Glaukos (NYSE:GKOS) Hits New 1-Year High at $134.77

Glaukos Co. (NYSE:GKOS - Get Free Report) shares hit a new 52-week high on Tuesday . The stock traded as high as $134.77 and last traded at $133.80, with a volume of 57731 shares trading hands. The stock had previously closed at $133.41.

Wall Street Analyst Weigh In

GKOS has been the topic of several analyst reports. Piper Sandler lifted their price target on shares of Glaukos from $110.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, August 1st. BTIG Research upped their target price on Glaukos from $112.00 to $131.00 and gave the company a "buy" rating in a research report on Monday, July 15th. Stifel Nicolaus increased their price target on Glaukos from $110.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday, June 5th. JPMorgan Chase & Co. boosted their price target on Glaukos from $108.00 to $110.00 and gave the stock an "overweight" rating in a research note on Thursday, May 2nd. Finally, StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a research report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $127.73.

Glaukos Stock Performance

The firm's 50 day simple moving average is $120.96 and its 200 day simple moving average is $106.96. The firm has a market capitalization of $6.81 billion, a price-to-earnings ratio of -46.97 and a beta of 1.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.68 and a current ratio of 5.48.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.52). The company had revenue of $95.70 million during the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm's quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.55) earnings per share. Sell-side analysts forecast that Glaukos Co. will post -2.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $13,216,581.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, COO Joseph E. Gilliam sold 2,500 shares of the company's stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $113.50, for a total value of $283,750.00. Following the completion of the transaction, the chief operating officer now owns 101,845 shares of the company's stock, valued at approximately $11,559,407.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $13,216,581.84. The disclosure for this sale can be found here. Insiders have sold a total of 46,000 shares of company stock valued at $5,550,740 over the last ninety days. Company insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Glaukos

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EFG Asset Management North America Corp. grew its stake in Glaukos by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier's stock valued at $3,216,000 after acquiring an additional 128 shares in the last quarter. Valeo Financial Advisors LLC increased its holdings in shares of Glaukos by 1.7% in the first quarter. Valeo Financial Advisors LLC now owns 8,932 shares of the medical instruments supplier's stock valued at $902,000 after purchasing an additional 150 shares during the last quarter. Corient Private Wealth LLC lifted its position in Glaukos by 0.7% during the fourth quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier's stock worth $1,969,000 after buying an additional 163 shares in the last quarter. AQR Capital Management LLC boosted its stake in Glaukos by 5.4% during the second quarter. AQR Capital Management LLC now owns 4,141 shares of the medical instruments supplier's stock worth $490,000 after buying an additional 211 shares during the last quarter. Finally, Xponance Inc. grew its holdings in Glaukos by 8.4% in the 2nd quarter. Xponance Inc. now owns 3,118 shares of the medical instruments supplier's stock valued at $369,000 after buying an additional 241 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.